1Faculty of Medicine, University of Novi Sad, Clinical Centre of Vojvodina, Clinic for Infectious Diseases.
2 Faculty of Pharmacy of Novi Sad, Business Academy University in Novi Sad.
3 Faculty of Medicine, University of Novi Sad, Clinical Centre of Vojvodina, Clinic for Hematology.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Treating HCV in people with hemophilia prevents the development of
end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC) and
greatly increases the quality of life for people living with
hemophilia. There are many obstacles in reaching the WHO goal of
globally eradicating HCV by 2030, mainly its scale, complexity, and
implementation. That is why many countries have implemented a
micro-elimination strategy: a pragmatic elimination approach in
populations with the most efficacy. The aim of this publication is to
present the morbidity and mortality rates, the clinical course and
treatment outcomes of chronic HCV infection in people with hemophilia
(PwH), as well as to show an example of a successfully conducted HCV
micro-elimination strategy among people with hemophilia in the Province
Material and Methods
|Figure 1. Diagnosis and treatment of HCV in patients with hemophilia in our center, from 1994. to 2020.|
|Table 1. Summary of patient population. Data are presented as percentages % (n) or mean ± SD.|
|Table 2. Characteristics of HCV infection in PWH in our cohort. HIV, human immunodeficiency virus; HBV, hepatitis B virus; ALT, aminotransferase; VL, viral load; HCC, hepatocellular carcinoma.|
|Figure 2. Summary of treatment outcomes in PWH with chronic HCV infection. HCV, hepatitis C virus; DAAs, direct-acting antivirals; IFN, interferon; SVR, sustained virologic response; PWH, persons with haemophilia; IFN, interferon; Peg IFN, pegylated interferon; RBV, ribavirine.|
|Table 3. Fisher's exact test, mortality of HCV positive and HCV negative persons with hemophilia in our cohort. HCV, hepatitis C virus.|